PHE885

Overview

PHE885 is an autologous T cell genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process that is being tested in patients with multiple myeloma.

SparkCures ID 376
Developed By Novartis
Generic Name PHE885
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Multiple Myeloma
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.